

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Dapagliflozin for treating chronic kidney disease [ID3866]

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> AstraZeneca (dapagliflozin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Kidney Care UK Kidney Research UK National Kidney Federation Network of Sikh Organisations Polycystic Kidney Disease Charity South Asian Health Foundation Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Anaesthetists of Great Britain & Ireland Association of Renal Technologists Association of Surgeons of Great Britain and Ireland British Association of Urological Nurses British Association of Urological Surgeons British Geriatrics Society British Renal Society British Transplantation Society NHS Blood and Transplant Primary Care Cardiovascular Society Primary Care Diabetes Society Renal Association Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons of England Royal Pharmaceutical Society Royal Society of Medicine Society for DGH Nephrologists 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> All Wales Therapeutic and Toxicology Centre Allied Health Professionals Federation Association of Renal Industries Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Welsh Kidney Patients Association <p><u>Comparators</u></p> <ul style="list-style-type: none"> Accord (captopril, enalapril, eplerenone, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, telmisartan, trandolapril, valsartan) Aspire (eplerenone) AstraZeneca (lisinopril) Aurobindo pharma (candesartan, carvedilol, enalapril, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan) Boehringer Ingelheim (telmisartan) Bristol laboratories (lisinopril)

Final stakeholder list for the technology appraisal of dapagliflozin for treating chronic kidney disease [ID3866].

Issue date: March 2021 © National Institute for Health and Care Excellence 2021. All rights reserved

- UK Clinical Pharmacy Association
- UK Renal Pharmacy Group

Others

- Department of Health and Social Care
- NHS England
- NHS Greenwich CCG
- NHS Lincolnshire East CCG
- Welsh Government

- Brown and Burk (irbesartan, lisinopril, losartan, ramipril)
- Consilient health (candesartan, eplerenone, irbesartan, losartan, perindopril, telmisartan)
- Daiichi Sankyo (olmesartan)
- Dexcel pharma (enalapril, losartan, valsartan)
- Glenmark pharma (olmesartan, perindopril, telmisartan)
- Lupin Healthcare (irbesartan)
- Martindale pharma (captopril)
- Novartis (valsartan)
- Organon (enalapril, losartan)
- Pfizer (quinapril)
- Sandoz (candesartan, losartan, ramipril, telmisartan)
- Sanofi (irbesartan, ramipril)
- Servier laboratories (perindopril)
- Takeda (azilsartan, candesartan)
- Ten pharma (captopril)
- Thame laboratories (captopril)
- Thornton & Ross (olmesartan)
- Tillomed laboratories (eplerenone, perindopril)
- Viatris. (candesartan, enalapril, eplerenone, eprosartan, fosinopril, lisinopril, losartan, olmesartan, perindopril, trandolapril, valsartan)
- Zentiva (eplerenone, irbesartan, ramipril)

Relevant research groups

- Centre for Kidney Research and Innovation
- Cochrane Kidney and Transplant
- Genomics England
- Kidney Research UK
- MRC Clinical Trials Unit
- National Institute for Health Research
- Society for Research in Rehabilitation
- Wellcome Trust

Associated Public Health Groups

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.